About Us

Redefining Interventional Cardiology

A French MedTech company at commercial and clinical stage, founded by Truffle Capital.

Carvolix is a French MedTech company at commercial and clinical stage, founded by Truffle Capital, with the ambition to become a global leader in the treatment of structural heart disease and ischemic stroke, two of the world’s leading causes of mortality and disability. Carvolix develops novel AI- and imaging-driven mini-robots that enable interventional cardiologists to perform complex procedures more effectively, alongside next-generation biomimetic heart valves.

We expect to make the cardiology catheterization lab as autonomous and efficient as an aircraft cockpit so that our radical innovations could potentially benefit millions of patients worldwide.

We’re applying our proven business builder model — uniting the capabilities of Truffle-founded companies to de-risk development, accelerate innovation, generate synergies and unlock value for shareholders.

Philippe Pouletty, M.D.
Founder of Carvolix, CEO of Truffle Capital, founder of several successful biotech and Medtech companies (including Abivax, Vexim, Symetis and Affluent Medical).

With Carvolix, we have the opportunity to build a global MedTech leader focused on developing and commercializing medical devices that could save the lives of hundreds of thousands of patients. It is a company with the potential to make a major impact.

Anne Lange
Chair of Directors of Carvolix.

We are bringing together three extremely innovative and synergistic MedTech companies into one – with the goal of augmenting the cardiac catheterization lab to treat far more patients suffering from valve dysfunction and brain stroke”. “In addition, we will boost synergies in R&D and commercialization between the three companies to enable the development and delivery of additional products, such as a robotically delivered mitral valve.

Sebastien Ladet
CEO of Carvolix.

Our vision

Expanding Access to Life-Saving Care

Millions of patients worldwide remain untreated each year, principally due to lack of access to the expertise required to treat them. As medical need increases and specialized clinicians remain scarce, the treatment gap continues to grow.

Carvolix aims to bridge this treatment gap by introducing AI-guided mini-robotic technologies that support clinicians during the most technically demanding steps of heart and stroke interventions.

By empowering interventional cardiologists, far more numerous than surgeons and interventional neuroradiologists, and highly receptive to innovation, we expand patients’ access to advanced procedures. Our platform enables a broader base of physicians to perform complex interventions with greater precision, confidence, and reproducibility, ultimately accelerating patient access to life-saving therapies.

This integrated approach accelerates development, strengthens execution, and supports scalable adoption across global markets.

Leadership

Executive Management

Sébastien Ladet, Ph.D.

Chief Executive Officer

Christophe de Vregille

Chief Financial Officer

Jorgen Hansen

Chief AI & Robotics

Céline Buard

Head of marketing and EU Commercialization

Professor Howard Herrmann, M.D.

Chief Medical Officer

Benjamin Renault, Ph.D.

Chief Development Officer Implants and Instruments

Pierre Berthet-Rayne, Ph.D.

Chief Technology Officer Robotics

Governance

Board of Directors

Anne Lange

Chair

Michel Therin

Vice-chairman

Dominique Carouge

Board member

Alain Chevallier

Senior Partner Truffle Capital

Liane Teplitsky

Board member

Philippe Pouletty, M.D.

CEO of Truffle Capital, Founder of Carvolix

Rute Fernandes

Board Observer

Patrick Coulombier

Board Observer

Prof Christian Latremouille, M.D.

Board Observer

Prof. Daniel Hayoz, M.D.

Board Observer

Advisory Board

Prof. Stephan Haulon, M.D.

Chairman of the advisory board, Professor of Vascular Surgery; Chair, Department of Vascular Surgery; former Chairman of the European Society for Vascular Surgery